Clinical Trial Update: Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

View source ↗

Summary

Completed clinical trial update assessing symptom improvement in patients with Non-Small-Cell Lung Cancer treated with a first-line EGFR tyrosine kinase inhibit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Cancer | Status: COMPLETED